Divergent Planning LLC Buys New Stake in Johnson & Johnson $JNJ

Key Points

• Divergent Planning LLC has acquired a new stake in Johnson & Johnson, purchasing 3,585 shares valued at approximately $548,000 during the 2nd quarter.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding analysts' estimates, with revenue of $23.74 billion, a 5.8% increase from the previous year.
• The company recently declared a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 2.9% and a payout ratio of 55.61%.

Divergent Planning LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,585 shares of the company's stock, valued at approximately $548,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 1.0%

Shares of NYSE:JNJ traded up $1.81 during mid-day trading on Friday, hitting $175.97. The stock had a trading volume of 25,535,971 shares, compared to its average volume of 8,957,323. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $423.80 billion, a PE ratio of 18.82, a P/E/G ratio of 2.26 and a beta of 0.40. The company's 50 day moving average is $172.42 and its 200-day moving average is $161.62.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on JNJ shares. Citigroup lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Bank of America upped their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Finally, Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $177.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.